- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-33-0184658

Violette Remedies Private Limited
About Violette Remedies Private Limited
Data last updated:
Violette Remedies Private Limited is a private limited company based in Thane, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 26 December 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74999MH2018PTC318741. Its GSTIN is 27AAGCV7336P1ZJ (Maharashtra). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors Shraddha Purey and Pradyumna Kumar Purey.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 2114 Solus Hiranandani Estate Ghodbunder Road Patlipada Thane West 400607, Maharashtra, India – 400607.
As per the financials filed for FY 2025, the company reported a revenue of ₹11.64 Cr, a growth of 17% compared to the previous year. For the same year it recorded a net profit of ₹1.77 Cr (net margin 15.2%) and EBITDA of ₹2.48 Cr (EBITDA margin 21.4%). Revenue has grown at a compounded annual rate (CAGR) of 14% over three years and 16% over five years.
The company has about 71 employees on its provident fund (EPFO) records.
Violette Remedies Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0184658).
Company details
Recognitions & Rankings of Violette Remedies
Contact details
Violette Remedies Private Limited's registered office is in Thane, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address2114 Solus Hiranandani Estate Ghodbunder Road Patlipada Thane West 400607, Maharashtra, India – 400607
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Violette Remedies Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Violette Remedies Private Limited
FY 2025 filings availableViolette Remedies Private Limited reported revenue of ₹11.64 Cr (up 17% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 16% over five years, including 17% growth in the latest year. EBITDA rose 33% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.48 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.77 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 21.4% | ||||
| Net Profit Margin | 15.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Violette Remedies Private Limited, buy the company report.
Board of directors of Violette Remedies Private Limited
Violette Remedies has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shraddha Purey | Director | 23 Nov 2019 | 6 Years 11 Months | Current |
| Pradyumna Kumar Purey | Director | 23 Nov 2019 | 6 Years 11 Months | Current |
Peer comparison
Violette Remedies Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Armein Pharmaceuticals Private Limited | ₹11.7 Cr (FY 2025) | 7.0% | Bamanva, Gujarat, India | |||
| Pollen Healthcure Private Limited | ₹11.65 Cr (FY 2025) | 39.0% | Pune, Maharashtra, India | |||
| Best Healthcare Private Limited | ₹11.64 Cr (FY 2024) | 18.0% | New Delhi, Delhi, India | |||
| Violette Remedies Private Limitedthis company | ₹11.64 Cr (FY 2025) | ₹1.77 Cr | 15.2% | 17.0% | 71 | Thane, Maharashtra, India |
| Aassk Pharmaceuticals Private Limited | ₹11.54 Cr (FY 2025) | 7.0% | Tiruvallur, Tamil Nadu, India |
To see the full peer comparison of Violette Remedies Private Limited, buy the company report.
Auditor
Violette Remedies Private Limited is audited by SINGHEE & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SINGHEE & ASSOCIATES | FY 2023 | 140292W |
Shareholding
The shareholding of Violette Remedies Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Violette Remedies Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Violette Remedies Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Violette Remedies Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Violette Remedies Private Limited has a workforce of 71 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 71 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 |
To see the full employee and EPFO history of Violette Remedies Private Limited, buy the company report.
GST
Violette Remedies has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAGCV7336P1ZJ | Maharashtra | Active | 27 Feb 2019 |
| 18AAGCV7336P1ZI | Assam | Active | 19 Jan 2024 |
To see the full GST registrations and return filing status of Violette Remedies Private Limited, buy the company report.
Recent activity
Violette Remedies Private Limited has 4 board changes on record since 2019: 2 appointments and 2 cessations. The latest: Anita Rawat ceased to be Director on 24 Dec 2019.
Frequently asked questions
Violette Remedies is an active private limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 26 December 2018 (8+ years old) and is registered under CIN U74999MH2018PTC318741.
Violette Remedies has 2 current directors:
- Shraddha Purey - Director
- Pradyumna Kumar Purey - Director
The latest financial statements of Violette Remedies on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Violette Remedies is 27AAGCV7336P1ZJ, registered in Maharashtra. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 18AAGCV7336P1ZI (Assam).
The CIN (Corporate Identification Number) of Violette Remedies is U74999MH2018PTC318741. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Violette Remedies was incorporated on 26 December 2018, making it 8+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Violette Remedies by revenue are Armein Pharmaceuticals Private Limited, Pollen Healthcure Private Limited, Best Healthcare Private Limited, Aassk Pharmaceuticals Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (wholesale trading).
Anita Rawat ceased to be Director on 24 Dec 2019. Chander Mohan Negi ceased to be Director on 24 Dec 2019. Pradyumna Kumar Purey was appointed as Director on 23 Nov 2019. Violette Remedies has 4 board changes on record in total.
Yes, Violette Remedies is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0184658).
The registered office of Violette Remedies is at 2114 Solus Hiranandani Estate Ghodbunder Road Patlipada Thane West 400607, Maharashtra, India – 400607.
Violette Remedies operates in the pharma industry, in the drug formulation and development segment.

